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Histamine and Delirium: Current
Opinion
Paul L. Chazot1* , Laura Johnston1, Edel Mcauley2 and Stephen Bonner2
1 Department of Biosciences, Durham University, Durham, United Kingdom, 2 Intensive Care, South Tees Hospitals NHS
Foundation Trust, The James Cook University Hospital, Middlesbrough, United Kingdom
Delirium is a very common, but refractory clinical state, notably present in intensive care
and in the growing aging community. It is characterized by fluctuating disturbances
in a number of key behavioral features, namely cognition, mood, attention, arousal,
and self-awareness. Histamine is arguably the most pleotropic neurotransmitter in the
human brain, and this review provides a rationale, and proposes that this neuroactive
amine plays a role in modulating the characteristic features of delirium. While centrally
permeable H1 and H2 histamine receptor antagonists have pro-delirium potential, we
propose that centrally permeable H3 histamine receptor antagonists may provide an
exciting new strategy to combat delirium. The Histamine H4 receptor may also have an
indirect inflammatory neuroglial role which requires further exploration.
Keywords: histamine, H3 receptor, delirium, CNS, autoreceptor, heteroreceptor
INTRODUCTION
What Is Delirium?
Delirium is a very common, but refractory clinical state, notably commonly present in intensive care
and in the growing aging community, with occurrence rates ranging from 14 to 56%, and hospital
mortality rates ranging from 25 to 33% (Leslie and Inouye, 2011). It is characterized by fluctuating
disturbances in arousal, attention, cognition, mood, and self-awareness, which can arise acutely,
either in the absence of prior intellectual impairment or superimposed on chronic intellectual
impairment in the growing aging population. The rise and development of delirium has been
associated with increased morbidity, persistent functional decline, increased nursing time, higher
hospital costs, increased length of hospital stay, and higher rates of nursing car home placement.
Worryingly, delirium is a common, serious, and refractory source of mortality in intensive and
community care across the age range, but is only recently being addressed in the United Kingdom,
Europe and worldwide (Leslie and Inouye, 2011). Delirium in older hospitalized patients is of
particular concern because patients aged 65 years and over currently account for more than half
of all days spent in hospital care.
Delirium is a neurobehavioral syndrome caused by dysregulation of neuronal activity
often secondary to serious systemic disturbances. Over time, a number of theories have
been proposed in an attempt to explain the processes leading to the development of
delirium (Maldonado, 2015; Herling et al., 2018). Each proposed complementary theory has
focused on combinations of specific mechanisms or pathological processes (e.g., dopamine
excess or acetylcholine deficiency, inflammatory responses), observational qualitative evidence
(e.g., sleep deprivation, aging), or empirical scientific data (e.g., specific pharmacological
agents such as opioids) or intraoperative hypoxia state association with postoperative
delirium) (Maldonado, 2013; Egberts et al., 2018). The literature suggests that many
factors or mechanisms included in these theories lead to a final common outcome
associated with an alteration in neurotransmitter synthesis, function, and/or availability that
triggers the complex behavioral and cognitive changes reported in delirium. In general,
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the most commonly described neurochemical changes associated
with delirium include deficiencies in acetylcholine and/or
melatonin, together with excess in glutamate and monoamines
dopamine and noradrenalin, and bi-directional activity
alterations (e.g., decreased or increased activity, depending on
delirium presentation and trigger) in serotonin, γ-aminobutyric
acid (GABA) and/or, importantly, histamine (Maldonado, 2013).
The unknown nature of etiology for most types of delirium
and the complete lack of placebo-controlled Randomized
Controlled drug Trials, the lack of any FDA-approved drug
treatment for delirium and the wide ranging nature of drugs with
multiple chemical neurotransmitter pathways affected (variable
across NHS Trust hospitals) used to treat it is clearly a major
problem. Furthermore the lack of effective non-pharmacological
approaches is also problematical (Wade et al., 2015, 2019;
Richards-Belle et al., 2018) Without understanding more about
the underlying nature of the pathways involved how can we hope
to effectively and rationally treat it?
In this short commentary, we offer a rationale for a new
pharmacological strategy to combat delirium. We propose that
central histamine is a significant player in all of the clinical
features of delirium; while H1 and H2 histamine-targeted
antihistamines should be treated with care, a centrally acting
histamine H3 receptor antagonist, with appropriate diurnal
pharmacokinetic properties, may provide a novel and effective
strategy for preventing or combatting delirium. We discuss the
key evidence base and potential mechanisms underpinning these
proposals and clinical implications.
HISTAMINE AND ANATOMICAL
FRAMEWORK RELEVANCE TO
DELIRIUM COGNITION, MOOD AND
WAKEFULLNESS
Arousal stems from the wakefulness of a person and awareness is
the individual’s ability to perceive his/her environment. In both
these behavioral states, histamine has a primary role to play.
Diminished alertness, delayed reaction times, and somnolence
are common manifestations of allergy treatments with use of
classic first-generation (CNS-permeant) anti-histamines, thus
evidencing that histamine is required for arousal/wakefulness
and awareness/attention. The evidence became stronger with
the report that histidine decarboxylase (HDC) knockout mice,
which lack histamine, display increased paradoxical sleep,
sleep-wake cycle modifications, and are unable to remain
awake under diurnal high vigilance (narcolepsy) (Parmentier
et al., 2002). The mammalian, including human, waking state
is maintained by continual activation of neuromodulatory
aminergic neurotransmitters [dopamine, noradrenaline (NA),
acetylcholine and notably histamine], hypocretin/orexinergic
(Oxergic), and selective excitatory glutamatergic and inhibitory
GABAergic pathways (Korotkova et al., 2005; Yu et al., 2018).
Cortical activation is one of the physiological signs of wakefulness
and requires robust cholinergic, noradrenergic, serotonergic
and, importantly, histaminergic tones. Histamine controls these
features through the extensive influence of ascending branches
from the tuberomammillary nucleus (TMN) in the hypothalamus
to all parts of the brain, including the prefrontal cerebral
cortex, various limbic regions and the basal ganglia (Yu
et al., 2018). Monoaminergic neurons comprising noradrenergic
(locus coeruleus: LC), serotonergic (raphe nuclei, RN) and
histaminergic (TMN) neurons project to the cerebrocortex,
thalamus and brainstem are known together as the center of
sleep regulation (Oh et al., 2018; Yu et al., 2018). Furthermore,
Oxergic cell bodies in the hypothalamus densely project to
LC, TM and RN, which suggests a strong link between
monoaminergic and Oxergic neurons, again in the control
of wakefulness. It is well established that the Oxergic wake-
active neurons provide a major excitatory drive onto TMN
histamine neurons (Lin et al., 2011), and this could be a key
way that orexin promotes arousal, through amplifying its effects
via the histaminergic system. During the wake state, TMN
histamine/GABA-ergic neurons are co-active in parallel and their
ascending histamine/GABA fibers release histamine and GABA
into the prefrontal cortex (PFC), neocortex (Ctx) and striatum
(Str) (Lin et al., 2011). Glutamatergic pyramidal neurons in the
PFC send excitatory projections back to the histamine neurons
in the TMN, reinforce wakefulness, attention and consciousness
(Lin et al., 2011). The Histamine-GABA-ergic neurons are
silenced during Non-REM sleep by preoptic GABAergic neurons.
Histamine-only projections from the TMN also excite cholinergic
neurons into the basal forebrain, and the axons of these
excited cholinergic neurons release acetylcholine throughout the
cortex (the fundamental basis for high attention together with
productive cognitive function). We suggest that when the brain is
exposed to these neuromodulators appropriately, we are wakeful,
attentive and conscious, importantly, without delirium. This this
overall neuronal anatomical framework provides the mechanistic
basis for the influence of histamine upon delirium, through auto-
and hetero-presynaptic and postsynaptic functions, respectively.
HISTAMINE RECEPTOR
SUBTYPE-DEPENDENT EFFECTS
Histamine elicits its physiological action via four G-protein
couple receptor (GPCR subtypes, namely H1, H2, H3, and H4
receptors, expressed widely and differentially throughout the
body, including the CNS (reviewed in Panula et al., 2015). In
terms of the brain, H1, H2, H3 receptors play clear roles in
neuronal function, post- and pre-synaptically, and, interestingly,
the H4R appears to influence neuronal function indirectly
through modulating activated microglia (Zhou et al., 2018).
Histamine driven H1 and H2 receptor-mediated actions are
mostly excitatory, while H3 receptors act as inhibitory auto-
and heteroreceptors (Panula et al., 2015). Histamine-mediated
excitation was blocked by a CNS-permeable H1 receptor
antagonist, mepyramine, in 78% of cells and by cimetidine,
a CNS-permeable H2 receptor antagonist, in 42% of cells
(Korotkova et al., 2005). Histamine H3 heteroreceptor function
modulates cholinergic, GABA-ergic, as well as noradrenergic
function (Panula et al., 2015) (Figure 1).
Frontiers in Pharmacology | www.frontiersin.org 2 April 2019 | Volume 10 | Article 299
fphar-10-00299 April 9, 2019 Time: 12:40 # 3
Chazot et al. Histamine and Delirium
FIGURE 1 | Schematic how manipulating the central histaminergic system by blocking the histamine receptors can potentially modify delirium symptom induction
and maintenance through manipulating levels of histamine (HIS) through autoreceptors, acetylcholine (Ach) and noradrenalin (NA), through heteroreceptors binding
to histamine receptors, acetylcholine receptor (AChR) and AdR (adrenergic receptors, respectively. (A) H1 and H2 histamine receptor antagonists. (B) H3 receptor
antagonists.
HISTAMINE H1 RECEPTOR CNS
PHYSIOLOGY
Histamine H1 receptors occur throughout the CNS, with
particular high densities in regions involved in arousal and
waking, notably the thalamus and cortex, and neurochemically
the cholinergic, noradrenergic, dopaminergic, and serotonergic
nuclei. H1 receptor activation causes excitation in many brain
regions (brain stem, thalamus, hypothalamus, cortex, amygdala,
striatum) through Gq11 protein and direct block of leak
K+ conductance or phospholipase C, inositol trisphosphate
(IP3), and diacylglycerol (DAG) mediation (discussed in Obara
et al., 2019). IP3 releases Ca2+ from internal stores and
activates a number of Ca2+-dependent processes, including the
opening of a cation channel of the transient receptor potential
canonical (TRPC) type or stimulation of a Na+–Ca2+-exchanger.
Furthermore, the elevated intracellular Ca2+ can stimulate NO
synthase and, consequently, guanylate cyclase. On the other
hand, Ca2+-dependent K+ channels can be opened, leading to
hyperpolarization and inhibition, for instance, in hippocampal
pyramidal neurons.
H2 HISTAMINE RECEPTOR CNS
PHYSIOLOGY
Histamine H2 receptors are also widely distributed in the
mammalian brain (reviewed in Panula et al., 2015). The highest
densities of histamine H2 receptors are found in the basal
ganglia, hippocampus, amygdala and cerebral cortex, with
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modest expression levels in the cerebellum and hypothalamus
(Panula et al., 2015; Monczor and Fernandez, 2016). A similar
distribution of the histamine H2 receptor occurs in the brain
of humans and rodents. H2 histamine receptor antagonists
decreased significantly the hypothalamic NA content by 21–32%.
Activation of the histamine H2 receptor in the brain inhibits
nerve cells and blocks long-lasting afterhyperpolarization and
accommodation of firing in cortical and thalamic neurons (Haas
and Reiner, 1988). However, if this afterhyperpolarization block
continues for an protracted period, it can lead to potentiation of
excitation in rodent and in human brain, resulting in enhanced
synaptic plasticity (Brown et al., 1995). Therefore, H2 receptor
antagonism can suppress plasticity. RT-PCR revealed that while
mRNA for the H1 receptor was expressed in 77% of isolated LC
neurons, mRNA for the H2 receptor was in 41% and H3 receptors
in 29% of LC neurons. These findings underline the coordination
between aminergic systems and suggest that the arousal induced
by the histamine system could involve excitation of noradrenergic
neurons in the LC (Korotkova et al., 2005).
H3 RECEPTORS CNS PHYSIOLOGY
H3 receptors, pre-synaptic inhibitory GPCRs, inhibit voltage-
activated Ca2+ channels, on the terminals of histaminergic
axons themselves (as an autoreceptor) and many types of
neurons (heteroreceptor), which leads to reduced transmitter
release of histamine, and acetylcholine, noradrenalin, serotonin,
GABA, glutamate (heteroreceptors), respectively (reviewed in
Panula et al., 2015). Despite H3 receptors being predominantly
presynaptic receptors, regulating the release of neurotransmitters
such as acetylcholine and histamine in most areas of the
brain, in a particular part of the brain, namely the striatum,
the vast majority of these receptors are actually postsynaptic,
affecting signaling throughout the basal ganglia. Because
the basal ganglia are centrally involved in several major
neurological and psychiatric disorders, this aspect requires
consideration. Constitutive activity in vivo and the possibility
of dimerization shown in vitro for the H3 receptor has been
reported (summarized in Panula et al., 2015), but relevance to
physiological function of these functional and structural features
and, therefore, to modulating delirium, is unclear.
H4 RECEPTORS CNS PHYSIOLOGY
A number of recent experimental studies suggest that systemic
inflammation contributes to the pathophysiology of delirium
in both elderly and post-trauma delirium. A common raised
inflammatory cytokine linked to delirium in these studies is
IL-6. Histamine via the histamine H4 receptor is known to
play a key role in activating systemic inflammation through
activation of microglia, mast cells and immune dendritic cells,
with consequent production of proinflammatory factors TNF-α
and, notably, IL-6 (Desai and Thurmond, 2011; Simon et al.,
2011; Vasunilashorn et al., 2015; Ngo et al., 2017; Zhou et al.,
2018). A rise in microglia H4R has been implicated in Parkinson’s
disease, in which delirium has been a recently recognized feature.
This offers a possible role for the H4R in the neuroinflammatory
components of delirium.
HISTAMINE RECEPTOR SUBTYPE
CONNECTIONS IN THE DELIRIUM
CLINICAL SETTING AND
WAKEFULLNESS
Histamine H1 and H2 Receptors
Drug-induced delirium is often seen in clinical practice. Even
before it was discovered that histamine was a transmitter in
the brain, first generation anti-histamines (i.e., H1 receptor
antagonists) were noted historically to be sedatives (eg., Monnier
et al., 1967). Interestingly, H1 receptor antagonists, for example,
doxepin (at low concentrations), are making a comeback to
treat primary insomnia (Yeung et al., 2015). Histamine and
H1Rs are involved in maintaining arousal and cognition in
humans, and that the severity of clinical symptoms is correlated
to the amount of antihistamine that has penetrated into the
brain (Tashiro et al., 2002). It was noted, as far back as the
1980s, that delirium was a rare side-effect of both H1 and H2
antagonists (reviewed in Yanai et al., 2017) (Table 1). First
generation H1 anti-histamines significantly increased daytime
sleepiness and nocturnal sleep quality. Some, including cetirizine
and hydroxyzine, seemed to also have negative influences
on mood states. Outpatients who received cetirizine and
hydroxyzine treatments reported higher scores on the depression,
anxiety, and fatigue sub-scales compared to those who received
desloratadine, levocetirizine, and rupatadine (Clegg and Young,
2011). The sedating antihistamines are non-specific in their
actions and often have marked anticholinergic effects. Features
of overdose include tachycardia, blood pressure disturbances,
dry mouth, ataxia, psychosis, convulsion and, notably, agitation
(Clegg and Young, 2011).
The second generation CNS-sparing H1 antihistamine,
betahistine is not normally known to induce delirium, but an
investigation in a side-effects databases did reveal several cases
in which delirium may have been present, even though the
term, delirium, was not actually used. In this case, delirium was
potentially due to the combination of an elevated betahistine
plasma level and, significantly, a damaged blood-brain barrier
due to cerebral infarctions, confirmed both by computed
tomography (CT) and Magnetic resonance imaging (MRI) scans
(Hoenders and Wilterdink, 2004). It is noted that caution is
often required when prescribing antihistamine H1 antagonists
for people at risk of delirium and considered individual patient
assessment is recommended. In contrast, a small, recent study
showed cyproheptadine, a first generation anti-H1 antihistamine,
with its range of diverse effects was proposed to be a potential
option for prevention of postoperative delirium. In this pilot
study, cyproheptadine significantly decreased the incidence, but
not severity of postoperative delirium (this may relate to its
central-permeability). In contrast, the main negative feature of
promethazine (another first generation H1 antihistamine) is
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TABLE 1 | The implication of histaminergic system and drugs to delirium.
Drug Selectivity CNS-
permeable?
Effects on
delirium?
Reference
Doxepin H1 Yes unknown Yeung et al., 2015
Cetirizine H1 Yes possible Clegg and Young,
2011
Hydroxyzine H1 Yes possible Clegg and Young,
2011
Desloratadine H1 No No Clegg and Young,
2011
Levocetirizine H1 No No Clegg and Young,
2011
Rupatadine H1 No No Clegg and Young,
2011
Betahistine H1 No Mixed data Hoenders and
Wilterdink, 2004
Cyproheptadine H1 Yes Decreased
incidence but
not severity
Page et al., 2009
Cimetidine H2 Yes Possible Cantú and Korek,
1991
Cimetidine H2 Yes Yes Nowak, 1980
Cimetidine H2 Yes Yes Fujii et al., 2012
Ranitidine H2 No Unusual Mauran et al., 2016
delirium, the probability of which can be predicted from the dose
ingested by the individual (Page et al., 2009).
Studies on the association between CNS negative symptoms
(psychosis, agitation, hallucinations, mental status changes,
disorientation, confusion, irritability, a greatly reduced level of
consciousness or hostility all underpinning delirium) and H2
blockers have been explored previously. These reactions generally
occur during the first 2 weeks of therapy and resolve within 3 days
of drug withdrawal, although long term use in critical care or the
community may prove problematical. The estimated incidence
of CNS negative symptoms is 0.2% or less in outpatients, but
significantly higher, 1.6 to 80% in long-term hospitalized patients.
CNS side effects such as mental confusion (major facet of
delirium) develop in elderly patients and in patients with severe
renal or hepatic impairment. Cimetidine is CNS-permeable in
the elderly and critically ill patients (with compromised blood-
brain barrier). Cimetidine is frequently associated with these
“delirium” reactions; however, no clear evidence exists that one
H2 blocker is more likely than another to cause such a reaction
(Cantú and Korek, 1991). It has been noted that for people at risk
of delirium, certain drug combinations are to be prescribed with
care. Caution is also required when prescribing antihistamine
H2 antagonists for people at risk of delirium and a considered
individual patient assessment is advocated. Many case studies
have been reported to support this policy. One example was a
“serious” case of severe mania leading to hospitalization in a 42-
year-old alcohol-dependent 4 days after ranitidine introduction
(Mauran et al., 2016). Histamine H2 receptor antagonists may
also cause acute or chronic cognitive impairment. These effects
are often associated with some of the H2-histamine receptor
antagonists, eg., cimetidine (Tagamet) again, but are unusual
with ranitidine (Zantac), potentially again due to their respective
CNS permeability (Mauran et al., 2016). An old study showed
that that a large dose of H2-receptor antagonists (50–259
micrograms ivt) decreased hypothalamic NA content (Nowak,
1980). A comparison was made between two groups of patients
in a small study who were treated with H2 antagonists or proton
pump inhibitors (PPI group) for anastomotic ulcer prevention
following surgical treatment of esophageal cancer. It was noted
that the incidence of delirium was significantly lower in the PPI
group than in the H2 group. Significantly, in the 11 patients from
the H2 group who developed delirium, discontinuation of H2
antagonists resulted in a significant reduction in the delirium
rate score. This study indicated that switch from H2 blockers
to PPIs reduced delirium and, thus, providing an appropriate
strategy to combat drug-induced delirium using antiulcer drugs
(Fujii et al., 2012). The ventrolateral preoptic nucleus is a sleep-
promoting nucleus located in the basal forebrain. A commonly
used intravenous anesthetic, propofol, had been reported to
induce sleep and augment the firing rate of neurons in
ventrolateral GABAergic preoptic nucleus, but the underlining
mechanism is yet to be clearly determined. Interestingly, the
propofol-induced inhibition of inhibitory postsynaptic currents
on noradrenalin-inhibited neurons have been shown to be
mediated by histaminergic H1 and H2 receptors (Liu et al., 2017).
Opioids and Histamine Interactions
An interaction between histaminergic and opioidergic systems
within the CNS was proposed three decades ago, suggesting that
analgesia produced by opioids may be associated with release
of histamine and the stimulation of histamine receptors at the
supraspinal (central) level (Nishibori et al., 1985). Many more
recent studies have shown that histamine receptor antagonists
can modulate the analgesic action of opioids, however, the site
and mode of action of this interaction differs between the spinal
or supraspinal level, and depends on the subtype of histamine
receptor (Mobarakeh et al., 2002, 2006, 2009; Stein et al., 2016).
A series of studies have also shown than in H1R and H2R
KO mice, morphine-induced antinociception was significantly
augmented when compared to the wild-type controls in models
of acute pain. Therefore, anti-histamines should be prescribed
with caution in people at risk of delirium, but this should be
tempered by the observation that untreated severe pain can itself
trigger delirium.
Rationale for Use of H3 Antagonists for
Future Development?
Cortical activation (EEG desynchronization) is one of the
salient signs of wakefulness, attention and enhanced cognitive
function, and requires high histaminergic, and cholinergic,
noradrenergic, and serotonergic tones, controlled by H3 auto-
and heteroreceptor action, respectively. Arousal induced by
the histamine system through the H3 histamine heteroreceptor
blockade is believed to largely involve excitation of noradrenergic
neurons in the LC. As discussed above, the Histamine H3
receptor is expressed on and controls a population of the TM
histamine/GABA-ergic neurons which are co-active in parallel
and their ascending histamine/GABA fibers release histamine
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and GABA onto the PFC. Glutamatergic pyramidal neurons
in the PFC send excitatory projections back to the histamine
neurons in the TMN, reinforcing wakefulness, attention and
consciousness. Selective blockade of the H3-autoreceptor with
an H3 receptor antagonist would be predictive to drive this
positive reinforcement.
Histamine promotes wakefulness by tonic control over sleep-
generating mechanisms in the preoptic/anterior hypothalamus,
and cholinergic neurons seem to be implicated. The role
of histamine indicates that the histaminergic system also
influences attention and learning and memory performance
by modulating the release of ACh, although some cognitive
effects of histamine and histaminergic agents occur independent
of ACh. H3R antagonists are well known to enhance
cognition and rescue cognitive deficits in preclinical models
and modulate neurotransmission (Chazot, 2010), through,
in particular, acetylcholine (ACh) release in the cortex and
hippocampus, two key brain areas involved in memory
processing. It has been recently shown that histamine H3
receptor antagonist/inverse agonists require the integrity of
brain histamine system to successfully elicit physiological
and procognitive effects in the mouse (Provensi et al., 2016).
Perfusion of the TMN with the H3 inverse agonist/antagonist
(ABT-239) differentially increased histamine release from the
TMN, NBM, and PFC, but not from the STR or NAcc.
When administered locally, ABT-239 (H3 receptor antagonist)
again increased histamine release from the NBM, but not
from the NAcc. As defined by their sensitivity to ABT-239,
histaminergic neurons establish distinct pathways according
to their terminal projections, and can differentially modulate
neurotransmitter release in a brain region-specific manner
(Munari et al., 2013; Provensi et al., 2016). This implies
independent functions of subsets of histamine neurons according
to their terminal projections, with relevant consequences
for the development of specific compounds that affect only
subsets of histamine neurones, thus increasing target specificity.
The selective mode of action is currently believed to be
due to the respective levels of presynaptic H3Rs expressed
on the TMN and cholinergic neurons (Giannoni et al.,
2009). This requires formal confirmation. Overall, we provide
an anatomical, pharmacological and physiological rationale
for developing a CNS-permeable H3 histamine receptor
antagonist/inverse agonist as a strategy for combatting the range
of components of delirium.
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